We've found
13,253
archived clinical trials in
Arthritis
We've found
13,253
archived clinical trials in
Arthritis
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
Updated: 8/3/2015
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
Updated: 8/3/2015
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
Click here to add this to my saved trials
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
Updated: 8/3/2015
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
Updated: 8/3/2015
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
Click here to add this to my saved trials
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
Updated: 8/3/2015
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
Updated: 8/3/2015
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
Click here to add this to my saved trials
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
Updated: 8/3/2015
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
Updated: 8/3/2015
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
Click here to add this to my saved trials
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
Updated: 8/3/2015
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
Updated: 8/3/2015
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
Click here to add this to my saved trials
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
Updated: 8/3/2015
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
Updated: 8/3/2015
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
Click here to add this to my saved trials
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
Updated: 8/3/2015
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
Updated: 8/3/2015
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
Click here to add this to my saved trials
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
Updated: 8/3/2015
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
Updated: 8/3/2015
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
Click here to add this to my saved trials
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
Updated: 8/3/2015
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
Updated: 8/3/2015
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
Click here to add this to my saved trials
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
Updated: 8/3/2015
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
Updated: 8/3/2015
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
Click here to add this to my saved trials
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
Updated: 8/3/2015
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
Updated: 8/3/2015
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
Click here to add this to my saved trials
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
Updated: 8/3/2015
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
Updated: 8/3/2015
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
Click here to add this to my saved trials
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
Updated: 8/3/2015
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
Updated: 8/3/2015
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
Click here to add this to my saved trials
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
Updated: 8/3/2015
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
Updated: 8/3/2015
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
Click here to add this to my saved trials
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
Updated: 8/3/2015
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
Updated: 8/3/2015
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
Click here to add this to my saved trials
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
Updated: 8/3/2015
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
Updated: 8/3/2015
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
Click here to add this to my saved trials
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
Updated: 8/3/2015
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
Updated: 8/3/2015
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
Click here to add this to my saved trials
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
Updated: 8/3/2015
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
Updated: 8/3/2015
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
Click here to add this to my saved trials
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
Updated: 8/3/2015
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
Updated: 8/3/2015
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
Click here to add this to my saved trials
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
Updated: 8/3/2015
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
Updated: 8/3/2015
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
Click here to add this to my saved trials
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
Updated: 8/3/2015
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip
Updated: 8/3/2015
A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip
Status: Enrolling
Updated: 8/3/2015
Click here to add this to my saved trials
Exercise Plus Activity Strategy Training for Osteoarthritis
Updated: 8/3/2015
Exercise Plus Activity Strategy Training for Older Adults With Osteoarthritis
Status: Enrolling
Updated: 8/3/2015
Exercise Plus Activity Strategy Training for Osteoarthritis
Updated: 8/3/2015
Exercise Plus Activity Strategy Training for Older Adults With Osteoarthritis
Status: Enrolling
Updated: 8/3/2015
Click here to add this to my saved trials
Patient and Provider Interventions for Managing Osteoarthritis in Primary Care
Updated: 8/4/2015
Patient and Provider Interventions for Managing Osteoarthritis in Primary Care
Status: Enrolling
Updated: 8/4/2015
Patient and Provider Interventions for Managing Osteoarthritis in Primary Care
Updated: 8/4/2015
Patient and Provider Interventions for Managing Osteoarthritis in Primary Care
Status: Enrolling
Updated: 8/4/2015
Click here to add this to my saved trials
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
Updated: 8/6/2015
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
Updated: 8/6/2015
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
Click here to add this to my saved trials
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
Updated: 8/6/2015
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
Updated: 8/6/2015
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
Click here to add this to my saved trials
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
Updated: 8/6/2015
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
Updated: 8/6/2015
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
Click here to add this to my saved trials
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
Updated: 8/6/2015
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
Updated: 8/6/2015
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
Click here to add this to my saved trials
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
Updated: 8/6/2015
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
Updated: 8/6/2015
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
Click here to add this to my saved trials
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
Updated: 8/6/2015
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
Updated: 8/6/2015
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
Click here to add this to my saved trials
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
Updated: 8/6/2015
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
Updated: 8/6/2015
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
Click here to add this to my saved trials
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
Updated: 8/6/2015
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
Updated: 8/6/2015
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
Click here to add this to my saved trials
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
Updated: 8/6/2015
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
Updated: 8/6/2015
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
Click here to add this to my saved trials
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
Updated: 8/6/2015
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
Updated: 8/6/2015
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
Click here to add this to my saved trials
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
Updated: 8/6/2015
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
Updated: 8/6/2015
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
Click here to add this to my saved trials
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
Updated: 8/6/2015
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
Updated: 8/6/2015
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
Click here to add this to my saved trials
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
Updated: 8/6/2015
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
Updated: 8/6/2015
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
Click here to add this to my saved trials
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
Updated: 8/6/2015
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
Updated: 8/6/2015
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
Click here to add this to my saved trials
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
Updated: 8/6/2015
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
Updated: 8/6/2015
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
Click here to add this to my saved trials
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
Updated: 8/6/2015
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
Updated: 8/6/2015
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
Click here to add this to my saved trials
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
Updated: 8/6/2015
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
Updated: 8/6/2015
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status: Enrolling
Updated: 8/6/2015
Click here to add this to my saved trials
Safety and Efficacy of AMG 827 in Subjects With RA
Updated: 8/14/2015
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 8/14/2015
Safety and Efficacy of AMG 827 in Subjects With RA
Updated: 8/14/2015
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 8/14/2015
Click here to add this to my saved trials
Safety and Efficacy of AMG 827 in Subjects With RA
Updated: 8/14/2015
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 8/14/2015
Safety and Efficacy of AMG 827 in Subjects With RA
Updated: 8/14/2015
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 8/14/2015
Click here to add this to my saved trials
Safety and Efficacy of AMG 827 in Subjects With RA
Updated: 8/14/2015
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 8/14/2015
Safety and Efficacy of AMG 827 in Subjects With RA
Updated: 8/14/2015
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 8/14/2015
Click here to add this to my saved trials
Safety and Efficacy of AMG 827 in Subjects With RA
Updated: 8/14/2015
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 8/14/2015
Safety and Efficacy of AMG 827 in Subjects With RA
Updated: 8/14/2015
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 8/14/2015
Click here to add this to my saved trials
Safety and Efficacy of AMG 827 in Subjects With RA
Updated: 8/14/2015
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 8/14/2015
Safety and Efficacy of AMG 827 in Subjects With RA
Updated: 8/14/2015
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 8/14/2015
Click here to add this to my saved trials
Safety and Efficacy of AMG 827 in Subjects With RA
Updated: 8/14/2015
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 8/14/2015
Safety and Efficacy of AMG 827 in Subjects With RA
Updated: 8/14/2015
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 8/14/2015
Click here to add this to my saved trials
Safety and Efficacy of AMG 827 in Subjects With RA
Updated: 8/14/2015
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 8/14/2015
Safety and Efficacy of AMG 827 in Subjects With RA
Updated: 8/14/2015
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 8/14/2015
Click here to add this to my saved trials
Safety and Efficacy of AMG 827 in Subjects With RA
Updated: 8/14/2015
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 8/14/2015
Safety and Efficacy of AMG 827 in Subjects With RA
Updated: 8/14/2015
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 8/14/2015
Click here to add this to my saved trials
Safety and Efficacy of AMG 827 in Subjects With RA
Updated: 8/14/2015
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 8/14/2015
Safety and Efficacy of AMG 827 in Subjects With RA
Updated: 8/14/2015
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 8/14/2015
Click here to add this to my saved trials
Safety and Efficacy of AMG 827 in Subjects With RA
Updated: 8/14/2015
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 8/14/2015
Safety and Efficacy of AMG 827 in Subjects With RA
Updated: 8/14/2015
A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis
Status: Enrolling
Updated: 8/14/2015
Click here to add this to my saved trials